At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ELVN Enliven Treateutics
Post-Mkt 08-25 19:58:49 EDT
61.01
-0.14
-0.23%
盘后61.02
+0.01+0.02%
19:56 EDT
High62.00Low60.57Vol804.39K
Open61.90D1 Closing61.15Amplitude2.34%
Mkt Cap4.47BTradable Cap3.77BTotal Shares73.27M
T/O49.13MT/O Rate1.30%Tradable Shares61.73M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Argenx Se (ARGX)
TIPRANKS  ·  08-24 18:20
Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Argenx Se (ARGX)
Enliven Therapeutics CMO Helen Louise Collins Reports Disposal of 5,000 Common Shares Worth $293,612.17
Reuters  ·  08-20
Enliven Therapeutics CMO Helen Louise Collins Reports Disposal of 5,000 Common Shares Worth $293,612.17
Enliven Therapeutics, Inc. : Mizuho Raises Target Price to $73 from $62
THOMSON REUTERS  ·  08-18
Enliven Therapeutics, Inc. : Mizuho Raises Target Price to $73 from $62
Enliven initiated with an Outperform at William Blair
TIPRANKS  ·  08-18
Enliven initiated with an Outperform at William Blair
Enliven Therapeutics, Inc. : William Blair Initiates Coverage with Outperform Rating
THOMSON REUTERS  ·  08-18
Enliven Therapeutics, Inc. : William Blair Initiates Coverage with Outperform Rating
U.S. Research Roundup- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies
Reuters  ·  08-17
U.S. Research Roundup- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies
Enliven Therapeutics (ELVN) Gets a Buy from Stifel Nicolaus
TIPRANKS  ·  08-13
Enliven Therapeutics (ELVN) Gets a Buy from Stifel Nicolaus
Enliven Therapeutics Director Mika K. Derynck Sells USD 9.56 Million in Common Shares
Reuters  ·  08-07
Enliven Therapeutics Director Mika K. Derynck Sells USD 9.56 Million in Common Shares
Stifel Nicolaus Reaffirms Their Buy Rating on Enliven Therapeutics (ELVN)
TIPRANKS  ·  08-06
Stifel Nicolaus Reaffirms Their Buy Rating on Enliven Therapeutics (ELVN)
Climb Bio Q2 Net Loss Widens on Pipeline Advancement
Reuters  ·  08-06
Climb Bio Q2 Net Loss Widens on Pipeline Advancement
Aclaris Therapeutics Q2 Revenue Beats Analyst Estimates
Reuters  ·  08-06
Aclaris Therapeutics Q2 Revenue Beats Analyst Estimates
Enliven Therapeutics, Inc. : Jefferies Raises Target Price to $69 from $59
THOMSON REUTERS  ·  08-06
Enliven Therapeutics, Inc. : Jefferies Raises Target Price to $69 from $59
Enliven Therapeutics, Inc. : Guggenheim Cuts Target Price to $78 from $80
THOMSON REUTERS  ·  08-06
Enliven Therapeutics, Inc. : Guggenheim Cuts Target Price to $78 from $80
Enliven Therapeutics Q2 Net Loss Widens on Higher Expenses
Reuters  ·  08-06
Enliven Therapeutics Q2 Net Loss Widens on Higher Expenses
Enliven Net Loss Widens 28.2% to $32.5 Million in Q2 FY26
Reuters  ·  08-06
Enliven Net Loss Widens 28.2% to $32.5 Million in Q2 FY26
Enliven Therapeutics CMO Helen Louise Collins Disposes of USD 262,213 in Common Shares
Reuters  ·  07-22
Enliven Therapeutics CMO Helen Louise Collins Disposes of USD 262,213 in Common Shares
13D Filings
Dow Jones  ·  07-11
13D Filings
Enliven price target raised to $65 from $56 at H.C. Wainwright
TIPRANKS  ·  07-09
Enliven price target raised to $65 from $56 at H.C. Wainwright
Enliven Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $64 from $56
THOMSON REUTERS  ·  07-09
Enliven Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $64 from $56
Enliven Therapeutics Director Lori Anne Kunkel Disposes of USD 504,256 Common Shares
Reuters  ·  07-09
Enliven Therapeutics Director Lori Anne Kunkel Disposes of USD 504,256 Common Shares

Introduction

Company Name.
Enliven Treateutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
Issue price:
--